• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: H.I.G. Ventures - Clarus, Llc was granted 5,692,381 shares

    10/4/21 4:09:50 PM ET
    $BLUWU
    Business Services
    Finance
    Get the next $BLUWU alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    H.I.G. Ventures - Clarus, LLC

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Clarus Therapeutics Holdings, Inc. [ CRXT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/09/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/09/2021 A(1) 490,531 A $0.00 490,531 I See Footnote(2)
    Common Stock 09/09/2021 A(1) 2,731,094 A $0.00 2,731,094 I See Footnote(3)
    Common Stock 09/09/2021 A(1) 2,470,756 A $0.00 2,470,756 I See Footnote(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    H.I.G. Ventures - Clarus, LLC

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H.I.G. Bio-Clarus II, L.P.

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H.I.G. Bio-Clarus I, L.P.

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H.I.G.-GPII, Inc.

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    TAMER ANTHONY

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    MNAYMNEH SAMI

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    Explanation of Responses:
    1. Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer.
    2. The shares reported are held of record by H.I.G. Bio -- Clarus I, L.P ("Clarus I"). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of Clarus I and has sole voting and investment control over the shares owned by Clarus I. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus I. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
    3. The shares reported are held of record by H.I.G. Ventures - Clarus, LLC ("H.I.G. Ventures"). H.I.G. GP is the manager of H.I.G. Ventures and has sole voting and investment control over the shares owned by H.I.G. Ventures. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Ventures. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
    4. The shares reported are held of record by H.I.G. Bio -- Clarus II, L.P ("Clarus II"). H.I.G. GP is the general partner of Clarus II and has sole voting and investment control over the shares owned by Clarus II. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus II. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
    H.I.G. Ventures - Clarus LLC By: H.I.G.-GP II, Inc., its manager By: /s/ Richard Siegel _Title: Authorized Signatory 10/04/2021
    H.I.G. Bio - Clarus II, L.P. By: H.I.G.-GP II, Inc., its general partner By: /s/ Richard Siegel _Title: Authorized Signatory 10/04/2021
    H.I.G. Bio - Clarus I, L.P. By: H.I.G.-GP II, Inc., its general partner By: /s/ Richard Siegel Title: Authorized Signatory 10/04/2021
    H.I.G.-GP II, Inc. By: /s/ Richard Siegel Title: Authorized Signatory 10/04/2021
    By: /s/ Anthony Tamer 10/04/2021
    By: /s/ Sami Mnaymneh 10/04/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BLUWU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUWU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLUWU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: H.I.G. Ventures - Clarus, Llc was granted 5,692,381 shares

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      10/4/21 4:09:50 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 3 filed by new insider H.I.G. Ventures - Clarus, Llc

      3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      10/4/21 4:07:54 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 3: New insider Cbc Spvi Ltd claimed ownership of 3,602,287 units of Common Stock

      3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      9/24/21 6:05:09 AM ET
      $BLUWU
      Business Services
      Finance

    $BLUWU
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BLUWU
    SEC Filings

    See more

    $BLUWU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Blue Water Acquisition Corp. III Announces Closing of Upsized $253 Million Initial Public Offering

      GREENWICH, Conn., June 11, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company") (NASDAQ:BLUWU), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the closing of its upsized initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option, at an offering price of $10.00 per unit, resulting in gross proceeds of $253,000,000. The Company'

      6/11/25 1:24:00 PM ET
      $BLUWU
      Business Services
      Finance
    • Blue Water Acquisition Corp. III Announces the Upsized Pricing of $220 Million Initial Public Offering

      GREENWICH, Conn., June 10, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the upsized pricing of its initial public offering of 22,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. The units are expected to trade on The Nasdaq Global Market ("Nasdaq")under the ticker symbo

      6/10/25 6:00:00 AM ET
      $BLUWU
      Business Services
      Finance
    • Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc.

      GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUW), a special purpose acquisition company ("Blue Water"), today announced that its stockholders have voted to approve the proposed business combination (the "Business Combination") with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women ("Clarus") at its special meeting of stockholders (the "Special Meeting") held today, August 27, 2021. Holders of approximately 73.95% of Blue Water's issued and outstanding shares cast votes at the Special Meeting. Approximately 69.57% o

      8/27/21 12:58:37 PM ET
      $BLUW
      $BLUWU
      Business Services
      Finance
    • SEC Form EFFECT filed by Blue Water Acquisition Corp.

      EFFECT - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      10/8/21 12:15:18 AM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 424B3 filed by Blue Water Acquisition Corp.

      424B3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      10/7/21 5:07:36 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form S-1 filed by Blue Water Acquisition Corp.

      S-1 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      9/30/21 4:07:33 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Blue Water Acquisition Corp. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      10/8/21 4:24:24 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form SC 13G filed by Blue Water Acquisition Corp.

      SC 13G - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      9/24/21 6:06:39 AM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form SC 13D filed by Blue Water Acquisition Corp.

      SC 13D - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      9/21/21 4:18:31 PM ET
      $BLUWU
      Business Services
      Finance